BACKGROUND: In-stent restenosis is notoriously difficult to treat by repeat catheter intervention because of its propensity for aggressive recurrent neointimal formation. This study sought to assess the effectiveness and safety of the sirolimus-eluting stent in the treatment of in-stent restenosis. METHODS AND RESULTS: The study was designed as a prospective multicenter registry. We included 162 patients with in-stent restenosis of a native coronary artery who had a clinical indication for repeat intervention. Patients were scheduled for follow-up angiography at 6 months. The primary end point was in-lesion late loss. Follow-up angiography was performed in 155 patients. We obtained an in-lesion late loss of 0.08+/-0.49 mm and a binary restenosis rate of 9.7% (15/155), which prompted reintervention in 7.4% (12/162) at 9 months. The 9-month rate of death was 1.2% (2/162) and that of nonfatal myocardial infarction was 1.2% (2/162). CONCLUSIONS: Sirolimus-eluting stents were highly efficacious and safe in the treatment of in-stent restenosis. Our study provides rationale for the use of sirolimus-eluting stents in the treatment of in-stent restenosis.
BACKGROUND: In-stent restenosis is notoriously difficult to treat by repeat catheter intervention because of its propensity for aggressive recurrent neointimal formation. This study sought to assess the effectiveness and safety of the sirolimus-eluting stent in the treatment of in-stent restenosis. METHODS AND RESULTS: The study was designed as a prospective multicenter registry. We included 162 patients with in-stent restenosis of a native coronary artery who had a clinical indication for repeat intervention. Patients were scheduled for follow-up angiography at 6 months. The primary end point was in-lesion late loss. Follow-up angiography was performed in 155 patients. We obtained an in-lesion late loss of 0.08+/-0.49 mm and a binary restenosis rate of 9.7% (15/155), which prompted reintervention in 7.4% (12/162) at 9 months. The 9-month rate of death was 1.2% (2/162) and that of nonfatal myocardial infarction was 1.2% (2/162). CONCLUSIONS:Sirolimus-eluting stents were highly efficacious and safe in the treatment of in-stent restenosis. Our study provides rationale for the use of sirolimus-eluting stents in the treatment of in-stent restenosis.
Authors: Helge Möllmann; Albrecht Elsässer; Holger Nef; Steffen Schneider; Christoph A Nienaber; Gert Richardt; Michael Weber; Malte Kelm; Benny Levenson; Tassilo Bonzel; Ulrich Tebbe; Georg Sabin; Thomas Pfannebecker; Jochen Senges; Christian W Hamm Journal: Clin Res Cardiol Date: 2008-03-03 Impact factor: 5.460
Authors: Shirish Hiremath; Praveen Chandra; Devang Desai; R Sivakumar; S Selvamani; Anand Srinivasan; Madhu Paulose; Sajy Jose; B C Kalmath; Vilas P Magarkar; Abhijeet Pathak; Tushar Mhetre Journal: Indian Heart J Date: 2014-12-23
Authors: Richard P Konstance; Eric L Eisenstein; Kevin J Anstrom; Linda K Shaw; Robert M Califf; Robert A Harrington; David B Matchar; Kevin A Schulman; David F Kong Journal: J Med Syst Date: 2008-04 Impact factor: 4.460